Baseline Characteristics in the Phase 2 GOLDEN Study of IONIS-FB-LRx, an Investigational Antisense Oligonucleotide to Treat AMD-Associated Geographic Atrophy

Time: 9:30 am
day: Day Two

Details:

  • Assess GOLDEN baseline study characteristics
  • Infer GA growth rates – dependence on size, location and focality
  • Informing future trials

Speakers: